文献速递抗栓抗凝管理

肺栓塞初始抗凝治疗:溶栓、普通肝素、低分子肝素、磺达肝癸钠或直接口服抗凝药?

Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?
PubMed 文献 · Br J Clin Pharmacol · 2017-07-09

综述回顾血流动力学稳定肺栓塞患者初始抗凝策略,指出直接口服抗凝药在多项大型临床试验中不劣于标准治疗且便捷,但试验排除标准涵盖诸多相对禁忌证,故低分子肝素仍重要,部分情况仍需普通肝素。

要点

  • 直接口服抗凝药在大型试验中不劣于标准治疗,已成初始治疗首选。
  • 直接口服抗凝药的许多相对禁忌证是临床试验排除标准。
  • 低分子肝素在初始治疗中仍重要,部分情况仍需普通肝素。

核心结论

  • 直接口服抗凝药在肺栓塞初始治疗中不劣于标准治疗,因便捷性正成为首选。
  • 低分子肝素在初始肺栓塞治疗中将继续发挥重要作用,部分情况仍需普通肝素。

研究设计与样本

  • 综述,概述用于肺栓塞初始管理的抗凝药的生物物理、药代动力学和药效学特性。

主要发现

  • 多项大型临床试验显示直接口服抗凝药在肺栓塞初始治疗中不劣于标准治疗。
  • 直接口服抗凝药的许多相对禁忌证是临床试验的排除标准。

临床怎么用

  • 直接口服抗凝药因便捷性正成为肺栓塞初始治疗首选。
  • 存在直接口服抗凝药相对禁忌证时,低分子肝素仍为重要选择,部分情况仍需普通肝素。

局限性

  • 直接口服抗凝药的许多相对禁忌证是临床试验排除标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The initial treatment of haemodynamically stable patients with pulmonary embolism (PE) has dramatically changed since the introduction of low molecular weight heparins (LMWHs). With the recent discovery of the direct oral anticoagulant drugs (DOACs), initial treatment of PE will be simplified even further. In several large clinical trials it has been demonstrated that DOACs are not inferior to standard therapy for the initial treatment of PE, and because of their practicability they are becoming the agents of first choice. However, many relative contraindications to DOACs were exclusion criteria in the clinical trials. Therefore, LMWHs will continue to play an important role in initial PE treatment and in some cases there still is a role for unfractionated heparin (UFH). In this review we will give an overview of the biophysical, pharmacokinetic and pharmacodynamic properties of anticoagulants currently available for the initial management of PE. In addition, we will provide a comprehensive overview of the indications for the use of UFH, LMWHs and DOACs in the initial management of PE from a pharmacokinetic/-dynamic point of view.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Leentjens J, Peters M, Esselink AC, et al. Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs? Br J Clin Pharmacol. 2017. PMID: 28593681. doi:10.1111/bcp.13340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。